Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 04/12/20181 min de leitura
Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment." This draft guidance is intended to assist sponsors in the clinical development of drugs for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Idioma original da fonte: Federal Register — Food and Drug AdministrationAbrir o comunicado original →